Intellia Therapeutics (NASDAQ:NTLA) Upgraded to Hold at Wall Street Zen

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Monday.

Other research analysts have also recently issued reports about the company. William Blair cut Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, October 27th. Evercore ISI set a $8.00 price target on shares of Intellia Therapeutics and gave the company an “in-line” rating in a report on Tuesday, November 11th. Citigroup restated a “market outperform” rating on shares of Intellia Therapeutics in a research report on Tuesday, October 28th. Truist Financial reaffirmed a “buy” rating and set a $14.00 price objective (down previously from $25.00) on shares of Intellia Therapeutics in a report on Monday, November 10th. Finally, Wedbush reduced their price objective on Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Eleven research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $18.43.

Intellia Therapeutics Trading Down 1.3%

NASDAQ NTLA opened at $9.61 on Monday. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.25. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -2.25 and a beta of 2.13. The stock’s 50 day moving average is $15.33 and its two-hundred day moving average is $12.59.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.10. The business had revenue of $13.78 million during the quarter, compared to the consensus estimate of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.Intellia Therapeutics’s revenue was up 51.6% on a year-over-year basis. During the same quarter last year, the company earned ($1.34) EPS. On average, analysts predict that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Buying and Selling

In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of the company’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the sale, the chief accounting officer owned 55,266 shares in the company, valued at approximately $960,523.08. The trade was a 3.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in NTLA. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Intellia Therapeutics during the third quarter worth $30,000. Blue Bell Private Wealth Management LLC bought a new position in Intellia Therapeutics during the third quarter worth about $30,000. Advisory Services Network LLC acquired a new position in shares of Intellia Therapeutics during the 3rd quarter worth about $33,000. Headlands Technologies LLC acquired a new position in shares of Intellia Therapeutics during the 2nd quarter worth about $26,000. Finally, Danske Bank A S bought a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at about $50,000. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.